Central Retinal Artery Occlusion (CRAO) — Pathway
Sudden painless monocular vision loss — an 'eye stroke', manage as an acute stroke; suspect giant cell arteritis if >50.
Suspected GCA → immediate steroids: Age >50 with headache/jaw claudication/temporal tenderness/PMR/high inflammatory markers — suspect giant cell arteritis (GCA): immediate hi…
Step-by-step decision
Choose step by step as prompted; reaching an endpoint gives the management recommendation. You can go back a step or restart anytime.
🎓 Want to practice? Do a case challenge with this pathway → (get a case, choose management step by step, scored).
Full pathway
- [Decision] Manage as strokeSudden painless monocular vision loss — predominantly arteritic? (An 'eye stroke' = acute ischemic stroke of the retina. Sudden painless monocular vision loss (within seconds), relative afferent pupillary defect (RAPD), fundus showing retinal pallor + a cherry-red macula ± a visible embolus. Usually a carotid/cardiac embolus (ipsilateral carotid disease in ~50%), or giant cell arteritis (arteritic).)
- Suspected predominantly arteritic (GCA) → Suspected GCA → immediate steroids
- Non-arteritic / generally embolic → Acute CRAO → manage as stroke
- [End] Suspected GCA → immediate steroidsAge >50 with headache/jaw claudication/temporal tenderness/PMR/high inflammatory markers — suspect giant cell arteritis (GCA): immediate high-dose corticosteroids (IV methylprednisolone 1 g/day × 1–3 days) to protect the fellow eye, check ESR/CRP, rheumatology/ophthalmology consult, temporal artery biopsy; also assess as CRAO.
- [End] Acute CRAO → manage as strokeManage as an acute stroke ('time is retina', emergency stroke center): within 4.5 h of onset, IV thrombolysis (alteplase, assess contraindications per the stroke pathway) may be considered; ocular massage/anterior chamber paracentesis/IOP lowering have limited evidence — do not delay stroke evaluation. Urgent work-up: assess GCA in those >50 (ESR/CRP), carotid imaging, cardiac (echo/ECG), brain MRI (often with concurrent stroke); secondary prevention (antiplatelet, risk-factor control). Do not manage as an outpatient follow-up.
Source guidelines & references
- AHA scientific statement on CRAO management; AAO retinal artery occlusion guidance
This pathway is our own synthesis of the decision logic in the guidelines above (not the guideline verbatim); thresholds and workflows change as guidelines update — in practice follow the latest guideline, your institution's protocol and the individual patient.
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.